Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | USP8 | P40818 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415067 | 0.84 | L3MBTL1 (0.51) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3967035 | 0.76 | KDM4E (0.56) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL12775196 | 0.76 | KDM5A (0.36) | KDM4EALDH1A1L3MBTL1ARIDH1 | |
| SCHEMBL2176428 | 0.74 | L3MBTL1 (0.58) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL531211 | 0.74 | MAPK1 (0.33) | ALDH1A1L3MBTL1IMPDH2IMPDH1AR | |
| SCHEMBL1937421 | 0.74 | KDM4E (0.54) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4760466 | 0.74 | ALDH1A1 (0.45) | KDM4EALDH1A1L3MBTL1GAAAR | |
| SCHEMBL810127 | 0.74 | L3MBTL1 (0.33) | KDM4EALDH1A1L3MBTL1IMPDH2IMPDH1 | |
| SCHEMBL5857653 | 0.74 | TRPV4 (0.33) | ALDH1A1L3MBTL1IMPDH2IMPDH1AR | |
| SCHEMBL810776 | 0.74 | KDM4E (0.41) | KDM4EALDH1A1GAAMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-9464088-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8765734-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7601736-B2 | Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics | SK CHEMICALS CO., LTD. (KR) | 2009-10-13 | — | — | US | disclosed |
| EP-1706412-A4 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS CO LTD (KR) | 2009-03-18 | — | — | EP | disclosed |
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | SK CHEMICALS CO., LTD. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1706412-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK Chemicals, Co., Ltd. (KR) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005063768-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS, CO., LTD. (KR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 248/4885ALDH1A1 1457/4885MEN1 2382/4885 |
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | IL5, IL1B, P2RY4 | KDM4E 405/4885ALDH1A1 1008/4885MEN1 4806/4885 |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 248/4885ALDH1A1 1457/4885MEN1 2382/4885 |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 248/4885ALDH1A1 1457/4885MEN1 2382/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 248/4885ALDH1A1 1457/4885MEN1 2382/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 347/4885ALDH1A1 1373/4885MEN1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.